Session Details

F089 Psychocutaneous Medicine: From Diagnosis to Management

Mon, Mar 22, 3:30 PM - 5:30 PM
2 CME Available Forum

DESCRIPTION

Psychocutaneous disorders present important diagnostic and management challenges in dermatology. This session will address delusional infestation, body-focused repetitive behaviors, and factitious dermatitis, including psychosocial drivers and diagnostic mimickers. Speakers will examine the psychological burden of common conditions such as acne, psoriasis, and eczema, alongside distorted self-image, body dysmorphic disorder, and Zoom dysmorphia, highlighting red flags and screening strategies. Practical guidance will cover patient communication, psychopharmacology, and management of personality disorders in dermatologic practice. The interplay of stress, pruritus, and skin symptoms will also be considered. The interactive format encourages audience questions and discussion with the expert faculty.

LEARNING OBJECTIVES

1.

Recognize psychocutaneous disorders, such as delusional infestation, body-focused repetitive behaviors, and factitious dermatitis, and identify the associated psychiatric/psychosocial comorbidities.

2.

Evaluate the psychological impact of dermatologic diseases and identify distorted self-image, body dysmorphic disorder, and Zoom dysmorphia through red flags and screening methods.

3.

Develop management strategies for psychocutaneous conditions and personality disorders encountered in dermatology, incorporating effective communication, psychopharmacology, and stress management.

SCHEDULE

3:30 PM

The approach to the patient with delusional infestation

Mohammad Jafferany, MD

3:42 PM

Skin picking disorder and other body-focused repetitive behaviors: how to help your patients

Nicholas Brownstone, MD, FAAD

3:54 PM

Factitious dermatitis in adolescents: psychosocial drivers, dermatologic mimickers, and dermpath pearls

Alina G. Bridges, DO, FAAD

4:06 PM

Psychopharmacology in dermatology

John Y. M. Koo, MD, FAAD

4:18 PM

Q&A

Alina G. Bridges, DO, FAAD, Nicholas Brownstone, MD, FAAD, Mohammad Jafferany, MD, John Y. M. Koo, MD, FAAD

4:30 PM

The dermatologic iceberg: what clinical examination does not capture

Charbel Skayem, MD

4:42 PM

From distorted self-image to clinical recognition: Body Dysmorphic Disorder and Zoom Dysmorphia

George Kroumpouzos, MD, PhD, FAAD

4:54 PM

Engaging with patients who have personality disorders in dermatology

Mio Nakamura, MD, MS, FAAD

5:06 PM

Psychogenic pruritus: recognition and management

5:18 PM

Q&A

George Kroumpouzos, MD, PhD, FAAD, Mio Nakamura, MD, MS, FAAD, Charbel Skayem, MD

DIRECTOR

George Kroumpouzos, MD, PhD, FAAD

George Kroumpouzos, MD, PhD, FAAD

APDerm, Massachusetts, and Warren Alper Medical School at Brown University, Rhode Island

SPEAKERS

Alina G. Bridges, DO, FAAD

Alina G. Bridges, DO, FAAD

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Nicholas Brownstone, MD, FAAD

Nicholas Brownstone, MD, FAAD

Mohammad Jafferany, MD

Mohammad Jafferany, MD

Covenant HealthCare College of Medicine at Central MIchigan University, Saginaw, MI

John Y. M. Koo, MD, FAAD

John Y. M. Koo, MD, FAAD

University of California, San Francisco Medical Center

Mio Nakamura, MD, MS, FAAD

Mio Nakamura, MD, MS, FAAD

University of Michigan

Charbel Skayem, MD

Charbel Skayem, MD

DISCLOSURES

Alina G. Bridges, DO, FAAD

No financial relationships exist with ineligible companies.

Nicholas Brownstone, MD, FAAD

Neutrogena – Speaker(Honoraria); UCB – Speaker(Honoraria);

Mohammad Jafferany, MD

No financial relationships exist with ineligible companies.

John Y. M. Koo, MD, FAAD

AbbVie – Speaker(Honoraria); Amgen – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Galderma – Speaker(Honoraria); Leo Pharma – Advisory Board(Honoraria); Leo Pharma Inc. – Speaker(Honoraria); Pfizer Inc. – Speaker(Fees); Regeneron – Speaker(Honoraria); Sanofi – Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Speaker(Honoraria);

George Kroumpouzos, MD, PhD, FAAD

No financial relationships exist with ineligible companies.

Mio Nakamura, MD, MS, FAAD

Amgen – Investigator(Grants/Research Funding); argenx – Advisory Board(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Galderma – Investigator(Grants/Research Funding); janssen – Investigator(Grants/Research Funding); Leo Pharma – Advisory Board(Honoraria); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Oruka – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Sol-Gel Technologies – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding);